viecure

5680 Greenwood Plaza Blyd, Ste 350
Greenwood Village, CO 80111

+1 720-443-5420
info@viecure.com

CY 2023 Real World Testing Report for VieCure

Executive Summary

This is the test report for CY 2023 real world testing for our VieCure certified EHR solution. This is the companion document to our CY 2023 real world test plan that described our approach for conducting real world testing in CY 2023 and the testing measures we employed.

Our findings show that EHR is working in our production as it was certified. For each our CY 2023 Real World Testing Measures, we have recorded our results and findings. We did not discover any non-conformities or errors from our testing.

Our signed attestation of compliance with the real world testing requirements is on the following page.

viecure

Developer Attestation

This Real World Testing report is complete with all required elements, including measures that address all certification criteria and care settings. All information in this plan is up to date and fully addresses the health IT developer's Real World Testing requirements.

Authorized Representative Signature:

Heath McMillion

DATE 1/31/2024

viecure

viecure

General Information

Plan Report ID Number: VieCure-RWT-2023

Developer Name: VieCure, Inc

Product Name(s): VieCure

Version Numbers(s): 3.2

Certified Health IT Criteria: 315(b)(1)-(3), (b)(6), (c)(1), (e)(1), (f)(2), (f)(5), (g)(7)-(9), (h)(1)

Product List (CHPL) ID(s) and Link(s):

- 15.04.04.3066.VieC.03.01.1.210128
- https://chpl.healthit.gov/#/listing/10541

Developer Real World Testing Page URL: https://www.viecure.com/certifications-1

viecure

Timeline and Milestones for Real World Testing CY 2023

- Milestone 1Q-2023: Begin communication with clients to ask for their support and participation in real world testing. The goal is to have a sufficient number of clients committed for real world testing by the end of 1Q-2023.
    - STATUS: MET
- Milestone 2Q-3Q 2023. During the 2nd and 3rd quarter of CY 2023, the real world testing with clients will be scheduled and performed. It is expected that a preparatory call will be done with clients to prepare them for testing activities. Results will be documented in the test results section of the test methods and ultimately used to build the test report. If any non-compliances are observed, we will notify the ONC-ACB of the findings and make the necessary changes required.
    - STATUS: MET
- Milestone 4Q-2023. During the last quarter of the year, the CY 2024 real world test plan will be completed according to ONC and ONC-ACB requirements and expectations. Test plan will be prepared for submission before the end of the year.
    - STATUS: MET
- Milestone 1Q-2024. Submit RWT Test Report to ONC-ACB.
    - STATUS: MET

viecure

Standards Version Advancement Process (SVAP) Updates

For CY 2023 RWT testing, we tested with USCDI v1.

Standard (and version)	USCDI v1
Updated certification criteria and associated product	315.b.1, b.2, b.6, g.9, g.10
CHPL Product Number	15.04.04.3066.VieC.03.02.1.221215
Conformance measure	Measure 1 for 315.b.1 Measure 2 for 315.b.2 Measure 3 for 315.b.6 Measure 4 for 315.g.9 and g.10

viecure

RWT Measure #1. Transitions of Care

Associated Criteria: 315(b)(1), (h)(1)

Measurement Description

This measure is tracking and counting the number of messages with CCDAs attached successfully sent.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: number of messages with CCDAs attached successfully sent

Total: 0 for all clinics during dates of 4Q-2023

Analysis and Key Findings

Last year, our users elected to share patient records through an alternative exchange interface in lieu of Direct. However, we have confirmed our relied upon software HISP, EMRDirect, is working properly in a production setting.

Non-Conformities or Errors Discovered

During our testing, we did discover a small issue with respect to the user experience of C-CDA transition of care via Direct with our EMRDirect partner. EMRDirect still allowed for C-CDAs to be sent securely through Direct, but the upload of the C-CDA from VieCure to EMRDirect required some additional steps before sending that reduced usability. We have addressed the issue to improve usability experience.

viecure

RWT Measure #2. NewRx Prescriptions

Associated Criteria: 315(b)(3)

Measurement Description

This measure is tracking and counting how many NewRx electronic prescriptions were created and successfully sent from the EHR Module to a pharmacy destination over the course of a given interval. The interval for this measure will be three (3) months

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: Number successfully sent from the EHR Module to a pharmacy destination.

Total: 33,003 for all clinics during dates of 4Q-2023

Analysis and Key Findings

Electronic prescribing is a popular feature with our client base, and our results support its wide spread use. Our numbers for this metric have increased 4-fold over last year's totals.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. We did not make any changes to this measure from our original test plan.

viecure

RWT Measure #3. Error Rate in Problem/Medication/Allergy Incorporation from C-CDA

Associated Criteria: 315(b)(2)

Measurement Description

This measure metric is the error rate of the EHR Module incorporating problem/medication/allergy from C-CDAs into the respective patient records..

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: error rate of medications, allergies and problems incorporated from a received C-CDA

Result: 0%

Testing Metric/Measurement: number of reconciliation of medications, allergies and problems from a received C-CDA

Total: 0 for all clinics during dates of 4Q-2023

Analysis and Key Findings

Our clinicians are typically not receiving C-CDAs from other providers but additional internal testing and audit results do not indicate any errors or failures with the functionality.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. We did not make any changes to this measure from our original test plan.

viecure

RWT Measure #4. Quality Measure Success Rate

Associated Criteria: 315(c)(1)

Measurement Description

This measure is tracking the measure calculation of patients or episodes of care which meet the numerator criteria of the quality measures certified in the EHR as displayed in our system's CQM dashboard.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: calculation of patients or episodes of care which meet the numerator criteria of the quality measures certified in the EHR as displayed in our system's CQM dashboard

Measure	Num	Demo	Result
CMS68: Documentation of Current Medications in the Medical Record	8146	8281	98.40%
CMS69: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan	3592	4446	80.80%
CMS127: Pneumococcal Vaccination Status for Older Adults	2203	2210	99.70%
CMS165: Controlling High Blood Pressure	243	480	50.60%

Analysis and Key Findings

Our clients began using our CQM capabilities this year. The primarily worked with their own 3rd party registry, but we supplied the QRDA Cat I file and other data formats for their reporting.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. We did not make any changes to this measure from our original test plan.

viecure

RWT Measure #5. Number of Patients Given Access to Portal

Associated Criteria: 315(e)(1)

Measurement Description

This measure is tracking and counting how many patients are given login access to their patient portal account.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: number of patients given login access to their patient portal account

Total: 1941 for all clinics during 4Q-2023

Analysis and Key Findings

Our clients began using our patient portal this year. We expect this number to grow in the following years.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. We did not make any changes to this measure from our original test plan.

viecure

RWT Measure #6. Syndromic Surveillance Error Rate

Associated Criteria: 315(f)(2)

Measurement Description

This measure is recording the error rate in creating syndromic surveillance message.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: number of syndromic surveillance registries engaged

Total: 0 messages sent for all clinics during 2023

Error Rate: 0%

Analysis and Key Findings

The results align with the feedback we received from our clinician community that they do not use this functionality regularly in their practices. The functionality is enabled in our product system, but customers have yet to request to be onboarded with a public registry.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. We did not make any changes to this measure from our original test plan.

viecure

RWT Measure #7. Electronic Case Message Error Rate

Associated Criteria: 315(f)(5)

Measurement Description

This measure is recording the error rate in creating electronic case message.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: number of electronic case registries engaged

Total: 0 messages sent for all clinics during 2023

Error Rate: 0%

Analysis and Key Findings

The results align with the feedback we received from our clinician community that they do not use this functionality regularly in their practices. The functionality is enabled in our product system, but customers have yet to request to be onboarded with a public registry.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. We did not make any changes to this measure from our original test plan.

viecure

RWT Measure #8. Number of Different Applications/3rd Party Systems Using API Capabilities

Associated Criteria: 315(g)(7), (9)

Measurement Description

This measure is tracking and counting the number of organizations with an active syndromic surveillance registry interface.

Care Settings

Our EHR is primarily targeted to oncology practices, and our measures were designed for this setting in mind.

Testing Results

Testing Metric/Measurement: number of different systems or applications are connecting to the EHR via the API

Total: 0 for all clinics during 2023

Analysis and Key Findings

We did not have any requests to use our certified FHIR API functionality. Our customers are using other API connections for data exchange, but they have yet to onboard a client using FHIR, but the functionality is present in the production setting. Additional internal testing and audit results do not indicate any errors or failures with the functionality.

Non-Conformities or Errors Discovered

During our testing, we did not discover any errors or criteria non-conformities. We did not make any changes to this measure from our original test plan.